Bharat Biotech, ExcellGene consortium to develop variant-proof Covid vax
Switzerland’s ExcellGene SA has announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI) for co-developing a variant-proof coronavirus vaccine with India’s Bharat Biotech. The consortium is developing or designing a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern as well as other betacoronaviruses.
Business Standard - July 27, 2022View the full story here: https://www.business-standard.com/article/companies/bharat-biotech-excellgene-consortium-progress-to-develop-variant-proof-vax-122072601269_1.html